Pila Pharma AB, a clinical stage biotech company listed on Nasdaq First North GM in Stockholm, Sweden, is pioneering the development of XEN-D0501, a novel TRPV1 antagonist aimed at revolutionizing diabetes and obesity treatment. Explore our journey as we prepare for a phase 2a clinical trial to evaluate XEN-D0501's safety and potential effects on blood glucose and body weight in overweight or obese individuals with diabetes. | About PILA PHARMA